The global ocular
pain treatment market is expected to witness considerable growth due to
increasing awareness about the eye disorders, technological advancement in
ocular therapeutic and diagnostic test, and increasing number of lifestyle
related ocular diseases. In addition, increasing geriatric population and
increasing disposable income are further supporting the growth of the global
ocular pain market.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market/report-sample
The pharmaceutical companies are actively involved in the
research and development of drugs for ocular pain. Loteprednol etabonate, a
Mucus-Penetrating Particle platform technology based Phase III clinical trial
drug of Kala Pharmaceuticals, Inc., is nanotechnology based products for the
treatment of ocular pain.
Ocular pain is defined as the inflammation of middle layer
of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or
other tissues that surround the eye.
Many factors such as infection, allergy, surgery or trauma including
blow to the eye, foreign body and chemical injury can lead to ocular
inflammation. It is important to manage ocular pain, else it can affect other
parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature.
Ocular pain is caused by several conditions such as glaucoma, ocular herpes,
shingles, optic neuritis, dry eye and refractive error.
Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc., Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.
